MCID: HYP081
MIFTS: 51

Hypolipoproteinemia

Categories: Blood diseases, Cancer diseases, Genetic diseases, Metabolic diseases, Rare diseases

Aliases & Classifications for Hypolipoproteinemia

MalaCards integrated aliases for Hypolipoproteinemia:

Name: Hypolipoproteinemia 12 74 52 15
Lipoprotein Deficiencies 12 54
Lipoprotein Disorder 54 71
Hypolipoproteinaemia 12
Hypolipoproteinemias 43
Lipoprotein 17

Classifications:



External Ids:

Disease Ontology 12 DOID:1387
ICD9CM 34 272.5
MeSH 43 D007009
SNOMED-CT 67 363140000
ICD10 32 E78.6
UMLS 71 C0020623 C0596848

Summaries for Hypolipoproteinemia

NIH Rare Diseases : 52 Hypolipoproteinemia refers to unusually low levels of fats (lipids) in the blood. Low lipid levels may be caused by rare genetic conditions, or be a sign of another disorder such as overactive thyroid, anemia , undernutrition, cancer , chronic infection, or impaired absorption of foods from the digestive tract . Associated genetic disorders includes abetalipoproteinemia , familial hypobetalipoproteinemia , and chylomicron retention disease . Signs and symptoms in the the genetic or familial form of hypolipoproteinemia vary. In hypobetalipoproteinemia the low density lipoprotein (LDL) cholesterol levels are very low, yet people with this syndrome typically have no symptoms nor require treatment. Other forms result in absent or near absent LDL levels and can cause serious symptoms in infancy and early childhood. Treatment for hypoproteinemia varies depending on the underlying cause and signs and symptoms present in each individual.

MalaCards based summary : Hypolipoproteinemia, also known as lipoprotein deficiencies, is related to lipoprotein glomerulopathy and hepatic lipase deficiency. An important gene associated with Hypolipoproteinemia is ABCA1 (ATP Binding Cassette Subfamily A Member 1), and among its related pathways/superpathways are Metabolism and Metabolism of water-soluble vitamins and cofactors. The drugs Insulin glulisine and Insulin aspart have been mentioned in the context of this disorder. Affiliated tissues include heart, endothelial and liver, and related phenotypes are Decreased free cholesterol and Decreased LDL uptake

Wikipedia : 74 Hypolipoproteinemia, hypolipidemia, or hypolipidaemia (British English) is a form of dyslipidemia that... more...

Related Diseases for Hypolipoproteinemia

Diseases related to Hypolipoproteinemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1307)
# Related Disease Score Top Affiliating Genes
1 lipoprotein glomerulopathy 34.2 LPA LCAT APOE APOB APOA2
2 hepatic lipase deficiency 33.7 LPL APOE APOA1
3 familial lipoprotein lipase deficiency 33.7 LPL APOE APOC3 APOC2 APOB APOA1
4 hypoalphalipoproteinemia, primary, 2 33.2 APOA1 ABCA1
5 hyperlipoproteinemia, type i 33.0 LPL APOE APOC3 APOC2 APOB APOA1
6 hypoalphalipoproteinemia 33.0 LCAT APOA2 APOA1 ABCA1
7 apolipoprotein c-ii deficiency 33.0 LPL APOC2
8 apolipoprotein c-iii deficiency 32.8 LPL APOC3
9 hypercholesterolemia, familial, 2 32.7 APOE APOB
10 abdominal obesity-metabolic syndrome 1 32.7 MTTP MIR33A LPL APOB
11 hypobetalipoproteinemia, familial, 2 32.6 PCSK9 APOB ANGPTL3
12 niemann-pick disease, type c1 32.3 SCARB1 ABCG5 ABCG1 ABCA1
13 hyperlipoproteinemia, type v 32.2 LPL APOE APOC3 APOC2 APOB APOA1
14 fish-eye disease 31.8 LCAT APOA2 APOA1
15 stroke, ischemic 31.7 LPA APOE APOB ABCA1
16 hyperlipoproteinemia, type iv 31.5 LPL LPA CETP APOE APOC3 APOC2
17 homozygous familial hypercholesterolemia 31.5 PCSK9 APOE APOB APOA1 ABCG5 ABCA1
18 lecithin:cholesterol acyltransferase deficiency 31.4 LPL LCAT APOE APOB APOA2 APOA1
19 intermediate coronary syndrome 31.0 PCSK9 LPA APOB APOA1
20 cerebrovascular disease 30.9 LPL LPA APOE APOB APOA1 ABCA1
21 familial hyperlipidemia 30.8 MTTP LPL LPA LCAT CETP APOE
22 chylomicron retention disease 30.8 SAR1B MTTP APOB APOA1
23 peripheral artery disease 30.8 PCSK9 APOE APOB APOA1
24 amyloidosis 30.8 LPA APOE APOA2 APOA1
25 xanthomatosis 30.7 LPL LPA APOE APOB ABCA1
26 abetalipoproteinemia 30.6 SAR1B PCSK9 MTTP LPL LPA LCAT
27 aortic valve disease 2 30.6 PCSK9 LPA APOB
28 defective apolipoprotein b-100 30.6 PCSK9 LCAT APOE APOB
29 chronic kidney disease 30.6 LPL LPA LCAT CETP APOE APOB
30 non-alcoholic fatty liver disease 30.5 MTTP MIR33A LPL APOC3 APOB APOA1
31 cholelithiasis 30.5 SCARB1 APOE ABCG5
32 peripheral vascular disease 30.5 PLTP LPA LCAT CETP APOB APOA2
33 coronary stenosis 30.4 SCARB1 PCSK9 LPL CETP APOE APOB
34 cerebral atherosclerosis 30.4 LPA APOE APOA1
35 amyloidosis aa 30.4 LPA LCAT APOA1
36 carotid artery disease 30.3 LPA APOE APOB APOA2 APOA1
37 platelet glycoprotein iv deficiency 30.3 SCARB1 LPL APOE APOB
38 sitosterolemia 30.2 SCARB1 PCSK9 MTTP LCAT APOB APOA1
39 apo a-i deficiency 30.2 LCAT APOA1
40 silent myocardial infarction 30.1 LPA APOB APOA1
41 generalized atherosclerosis 30.1 LPA APOE APOB
42 huntington disease-like 1 30.1 SCARB1 LPA LCAT CETP APOE APOB
43 fetal macrosomia 30.0 LCAT APOB APOA1
44 sea-blue histiocyte disease 29.9 PCSK9 LCAT APOE
45 familial lcat deficiency 29.9 LCAT APOE APOA2 APOA1
46 hereditary amyloidosis 29.9 APOA2 APOA1
47 arteries, anomalies of 29.9 MIR33A LPA APOE APOB APOA1
48 cholesterol ester storage disease 29.9 LCAT APOB
49 familial apolipoprotein c-ii deficiency 29.7 LPL APOC3 APOC2
50 aortic atherosclerosis 29.7 PLTP LPL LPA CETP APOE APOB

Graphical network of the top 20 diseases related to Hypolipoproteinemia:



Diseases related to Hypolipoproteinemia

Symptoms & Phenotypes for Hypolipoproteinemia

GenomeRNAi Phenotypes related to Hypolipoproteinemia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased free cholesterol GR00340-A-2 8.65 ABCA1
2 Decreased LDL uptake GR00340-A-1 8.32 LPL

MGI Mouse Phenotypes related to Hypolipoproteinemia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.86 ABCA1 ABCG1 ABCG5 ANGPTL3 APOA1 APOA2
2 liver/biliary system MP:0005370 9.4 ABCA1 ABCG1 ABCG5 ANGPTL3 APOA1 APOB

Drugs & Therapeutics for Hypolipoproteinemia

Drugs for Hypolipoproteinemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 631)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Insulin glulisine Approved Phase 4 207748-29-6
2
Insulin aspart Approved Phase 4 116094-23-6 16132418
3
Insulin glargine Approved Phase 4 160337-95-1
4
Linagliptin Approved Phase 4 668270-12-0 10096344
5
Etanercept Approved, Investigational Phase 4 185243-69-0
6
Mirabegron Approved Phase 4 223673-61-8 9865528
7
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
8
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
9
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
10
Sevelamer Approved Phase 4 52757-95-6
11
Lovastatin Approved, Investigational Phase 4 75330-75-5 53232
12
Liraglutide Approved Phase 4 204656-20-2 44147092
13
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
14
Nevirapine Approved Phase 4 129618-40-2 4463
15
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
16
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
17
Pitavastatin Approved Phase 4 147526-32-7, 147511-69-1 6366718 5282452
18
Lorazepam Approved Phase 4 846-49-1 3958
19
Ziprasidone Approved Phase 4 146939-27-7 60854
20
Probucol Approved, Investigational Phase 4 23288-49-5 4912
21
Lixisenatide Approved Phase 4 320367-13-3
22
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
23
Glyburide Approved Phase 4 10238-21-8 3488
24
tannic acid Approved Phase 4 1401-55-4
25
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
26
Gemfibrozil Approved Phase 4 25812-30-0 3463
27
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
28
Polyestradiol phosphate Approved Phase 4 28014-46-2
29
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
30
Nifedipine Approved Phase 4 21829-25-4 4485
31
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
32
Nelfinavir Approved Phase 4 159989-64-7 64143
33
Calcium acetate Approved, Investigational Phase 4 62-54-4
34
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
35
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
36
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
37
Colestipol Approved Phase 4 26658-42-4
38
Alendronate Approved Phase 4 66376-36-1, 121268-17-5 2088
39
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
40
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
41
Losartan Approved Phase 4 114798-26-4 3961
42
Drospirenone Approved Phase 4 67392-87-4 68873
43
Lisinopril Approved, Investigational Phase 4 76547-98-3, 83915-83-7 5362119
44
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
45
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
46
Spironolactone Approved Phase 4 52-01-7, 1952-01-7 5833
47
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
48
Propranolol Approved, Investigational Phase 4 525-66-6 4946
49
Amiloride Approved Phase 4 2016-88-8, 2609-46-3 16231
50
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440

Interventional clinical trials:

(show top 50) (show all 1738)
# Name Status NCT ID Phase Drugs
1 Study of the Effects of Lovaza (Omega 3 Fatty Acids) On Lipoprotein Particles and Their Transcriptional Effects Unknown status NCT01301794 Phase 4
2 Effects of Dapagliflozin on Hyperlipidemia, Glycemic Control and Insulin Resistance in Type 2 Diabetic Patients (DAPHNIS Study) Unknown status NCT02577159 Phase 4 Dapagliflozin
3 Effectiveness and Tolerability of Early Initiation of Combined Lipid -Lowering Therapy Included Simvastatin and Fenofibrate vs Simvastatin Alone in Patients With Type 2 Diabetes Mellitus, Hypertriglyceridemia and Acute Coronary Syndrome Unknown status NCT02015988 Phase 4 Fenofibrate;Simvastatin
4 Pravastatin for Acute Myocardial Infarction With Minimally to Mildly Increased Levels of Serum Cholesterol Study That Evaluates the Effects of Pravastatin for Acute Myocardial Infarction With LDL-Cholesterol Levels of 70-129 mg/dl Unknown status NCT00688922 Phase 4 Pravastatin
5 The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a) Unknown status NCT02501850 Phase 4 Liraglutide;metformin
6 The Metabolic and Anti-Inflammatory Effects of Combined Ezetimibe and Simvastin Therapy, as Compared to Simvastatin Alone, in Patients With Chronic Proteinuric Nephropathy Unknown status NCT00861731 Phase 4 simvastatin;EZE/simvastatin;EZE/simvastatin
7 Effect of Vitamin D on Metabolic Parameters in Patients With the Metabolic Syndrome Unknown status NCT01237769 Phase 4 Vitamin D3
8 A Randomized, Double-blind, Placebo-controlled Trial of Dan-shen Extract in Patients With Stable Angina Pectoris Unknown status NCT02870764 Phase 4 Dan-shen extract;Placebo
9 The Efficacy and Safety of Niacin on Hyperphosphatemia in End Stage Renal Disease Patients Undergoing Haemodialysis Unknown status NCT03163576 Phase 4 Niacin;Phosphate Binder
10 The Effects of OMACOR on the LDL Sub-fraction in Korean Type 2 Diabetic Patients With Combined Hyperlipidemia Unknown status NCT00758927 Phase 4 Omega-3 acid 4 grams per day;Placebo control
11 A Multicenter, Open Labeled, Cross-Over Designed Prospective Study Evaluating the Effects of Lipid Lowering Treatment on Steroid Synthesis Unknown status NCT00433823 Phase 4 Atorvastatin, Ezetimibe
12 Effect of Liraglutide on Fatty Liver Content Evaluated by Proton-spectroscopy (1H-spectroscopy) and Lipoprotein Kinetic, in Patients With Type 2 Diabetes Unknown status NCT02721888 Phase 4 Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
13 Effects of Nicotinic Acid Plus Simvastatin Versus Simvastatin Alone on Carotid and Femoral Intima-Media Thickness in Patients With Peripheral Artery Disease (NASCIT)-A Randomized Controlled Trial Unknown status NCT00712049 Phase 4 simvastatin;Nicotinic Acid
14 Randomized Trial of the Association Between Low-Dose Statins and Nutraceuticals in High-intEnsity Statin-intoleRant patiENts With Very High Risk Coronary Artery diseasE Unknown status NCT02001883 Phase 4 Association low-dose statin and nutraceuticals
15 Effect of Statins on the Progression of the Intima-media Thickness of the Radial Artery After Radial Angioplasty Unknown status NCT00952770 Phase 4
16 Comparison of High-Dose Rosuvastatin Versus Low Statin Dose Plus Fenofibrate Versus Low Statin Dose Plus Niacin in the Treatment of Mixed Hyperlipidemia Unknown status NCT01010516 Phase 4 High-dose rosuvastatin;Statin plus fenofibrate;Statin plus niacin ER/laropiprant
17 Assessment of the Effects of Ezetimibe on Coronary Plaque Volume in Patients With Acute Coronary Syndrome Unknown status NCT01068093 Phase 4 Ezetimibe
18 An Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate Simvastatin 20 mg Plus Omacor 4g Compared to Simvastatin 20 mg Plus Placebo in Subjects With Mixed Dyslipidemia Unknown status NCT00678743 Phase 4 Omacor + simvastatin
19 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
20 Improving Glycaemic Control in Malaysian Patients With Type 2 Diabetes Mellitus With Insulin Pump Therapy Unknown status NCT03112538 Phase 4 Multiple daily injections of insulin
21 Personalized Medicine in HCV Chronic Infection. Endothelial Dysfunction and Subclinical Atheromatosis in Patients With HCV Infection. Characterization and Potential Reversibility With Direct Antiviral Agents. Unknown status NCT02802280 Phase 4
22 Effect of Rosuvastatin Therapy on HDL2 Level and Antiatherosclerotic Reverse Cholesterol Transport Process in Chinses CAD Patients With Hyperlipidemia Unknown status NCT02593487 Phase 4 Rosuvastatin 10mg/d group;Rosuvastatin 20mg/d group
23 Effects on Glycemic Variability and Glyco-metabolic Control of Metformin, Pioglitazone and Sitagliptin in Type 2 Diabetic Patients Unknown status NCT01895569 Phase 4 Metformin;Pioglitazone;Sitagliptin
24 Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 in Patients With Metabolic Syndrome Unknown status NCT00988364 Phase 4 Simvastatin;Vytorin;Placebo;Ezetimibe
25 Dose Related Decrease in Triglycerides in Patients With Hypertriglyceridemia and Treated With Lovaza. Unknown status NCT00934219 Phase 4 Omega-3-Acid Ethyl Esters
26 A 12-Week, Randomized, Open-Label, Multicenter Study Exploring Low-Density Lipoprotein Cholesterol Lowering Efficacy and Safety of Rosuvastatin 20 mg/Day Compared to10 mg/Day in Chinese Patients With Acute Coronary Syndromes Unknown status NCT02077257 Phase 4 Rosuvastatin
27 Effect of Linagliptin on Intestinal Triglyceride-rich-lipoprotein Metabolism in Type 2 Diabetic Patients Unknown status NCT02280174 Phase 4 linagliptin
28 Peripheral Artery Disease in Patients on Maintenance Hemodialysis: Risk Factors and the Effect of FIR Therapy Unknown status NCT01095549 Phase 4
29 The Impact of the Time of Drug Administration on the Effectiveness of Combined Treatment of Hypercholesterolemia With ROSuvastatin and EZEtimibe (ROSEZE) - A Single-center, Crossover, Open-label Study Unknown status NCT02772640 Phase 4 Rosuvastatin and Ezetimibe morning or evening administration
30 Can Alendronate Suppress Aortic and Coronary Artery Calcification and Improve Bone Mineral Density in Chronic Peritoneal Dialysis Patients? Unknown status NCT00299572 Phase 4 alendronate (Fosamax)
31 The Low HDL On Six Weeks Statin Therapy (LOW) Study Unknown status NCT00238004 Phase 4 Nicotinic acid
32 Randomized, Double-blind, Placebo-controlled Clinical Trial, to Evaluate the Efficacy and Tolerability of the Combination of Soy Isoflavones and Red Clover Extract (FITOGYN) in the Treatment of the Hot Flushes in Menopausal Women. Unknown status NCT01116310 Phase 4 Soy isoflavones (Glycine max L) and red clover extract (Trifolium pretense L);Placebo
33 Targeting Synovitis in Early Rheumatoid Arthritis (TaSER). Intensive Management of Early Rheumatoid Arthritis Using Either Clinical or Musculoskeletal Ultrasound Assessment of Synovitis − a Randomised Study With Blinded Outcome Assessments Unknown status NCT00920478 Phase 4
34 Effects of High Dose Simvastatin vs. Atorvastatin on Baseline Lipoprotein Profiles, Apo-A-1 and C Reactive Protein Unknown status NCT00736463 Phase 4 Simvastatin;Atorvastatin 80 mg
35 Living With Statins - The Impact of Cholesterol Lowering Drugs on Health, Lifestyle and Well-being Unknown status NCT02796378 Phase 4 Training+Simvastatin+Q10-placebo;Training+Simvastatin-placebo+Q10-placebo;Training+Simvastatin+Q10
36 The Effect of Mirabegron on Brown Adipose Tissue in Healthy Young White Caucasian and South Asian Men Unknown status NCT03012113 Phase 4 Mirabegron;Placebo Oral Capsule
37 The ACT-OUT Trial: ACTivity OUTcomes Based on the Consumption of a High Carbohydrate or High Fat Diet in Patients With Metabolic Syndrome Unknown status NCT01357382 Phase 4
38 Exercise Versus Extended-Release Niacin in Patients With Coronary Heart Disease and Low High-Density Lipoproteins (HDL) Cholesterol: Effect on Lipid Profile and Endothelial Function Completed NCT00298909 Phase 4 niaspan (extended-release niacin);niacin
39 Effect of PPAR-Delta Agonist on Lipoprotein Kinetics in Metabolic Syndrome Completed NCT00841217 Phase 4 GW501516;placebo pill
40 Acute Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon Completed NCT01155206 Phase 4 glucagon
41 Open-labelled, Single Arm, Phase IV Clinical Study to Evaluate the Impact of Rosuvastatin on Lipid Levels in Patients With Metabolic Syndrome (EFFORT) Completed NCT00815659 Phase 4 rosuvastatin
42 The Effect of Ezetimibe 10 mg, Simvastatin 20 mg and the Combination of Simvastatin 20 mg Plus 10 mg Ezetimibe on Low Density Lipoprotein (LDL)-Subfractions in Patients With Type 2 Diabetes Completed NCT01384058 Phase 4 ezetimibe;simvastatin;Ezetimibe 10/Simvastatin 20
43 Exploratory Study of the Effects of Omega-3-acid Ethyl Esters on the Lipid and Lipoprotein Profile in the Blood Completed NCT02839902 Phase 4 TAK-085
44 A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy Completed NCT02642159 Phase 4 Alirocumab;Statins;Ezetimibe;Fenofibrate;Nicotinic acid;Omega-3 fatty acids;Antihyperglycemic Drug
45 Efficacy of Almonds Added to Chronic Statin Therapy Completed NCT00603876 Phase 4
46 Efficacy of WelChol® as an Add-on to Simvastatin Therapy Completed NCT00753779 Phase 4 colesevelam HCl tablets, and simvastatin tablets;simvastatin tablets and colesevelam HCl placebo
47 Lipid-lowering and Vascular Effects of a Nutraceutical Combination in HIV-infected Patients on Stable Antiretroviral Therapy Completed NCT03470376 Phase 4
48 Fluvastatin 80 mg Ret. vs Combination With Ezetimibe 10 mg in Patients With High Cardiovascular Risk Completed NCT00814723 Phase 4 fluvastatin;Fluvastatin plus ezetimibe
49 The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis - a Single-center Randomized Controlled Study Completed NCT02765399 Phase 4 Liraglutide;Placebo
50 Berberine Effects on Clinical Symptoms and Metabolic Disturbance as an Adjunctive Therapy in Patients With Schizophrenia: a Randomized Double-blind Placebo-controlled Study Completed NCT03548155 Phase 4 Berberine;atypical antipsychotic;placebo

Search NIH Clinical Center for Hypolipoproteinemia

Cochrane evidence based reviews: hypolipoproteinemias

Genetic Tests for Hypolipoproteinemia

Anatomical Context for Hypolipoproteinemia

MalaCards organs/tissues related to Hypolipoproteinemia:

40
Heart, Endothelial, Liver, Breast, Kidney, Testes, Ovary

Publications for Hypolipoproteinemia

Articles related to Hypolipoproteinemia:

(show top 50) (show all 106)
# Title Authors PMID Year
1
Molecular basis of the familial chylomicronemia syndrome in patients from the National Dyslipidemia Registry of the Spanish Atherosclerosis Society. 61
30150141 2018
2
A Belgian consensus strategy to identify familial hypercholesterolaemia in the coronary care unit and its subsequent cascade screening and treatment: BEL-FaHST (The BELgium Familial Hypercholesterolaemia STrategy). 61
30270073 2018
3
Simplified Canadian Definition for Familial Hypercholesterolemia. 61
30093300 2018
4
Severe xanthomatosis in heterozygous familial hypercholesterolemia. 61
29778561 2018
5
Association Between Blood Lipid Profiles and Atrial Fibrillation: A Case-Control Study. 61
29885277 2018
6
Microsomal transfer protein (MTP) inhibition-a novel approach to the treatment of homozygous hypercholesterolemia. 61
24987866 2014
7
Significant association between hypolipoproteinemia(a) and lifetime risk of cancer: an autopsy study from a community-based Geriatric Hospital. 61
25164551 2014
8
[Study on medical pattern of traditional Chinese medicine and western medicine diagnosis and treatment of hypertension patients in 30 034 cases in real world]. 61
25532374 2014
9
Emerging therapeutic agents to lower lipoprotein (a) levels. 61
23041907 2012
10
Extreme xanthomatosis in patients with both familial hypercholesterolemia and cerebrotendinous xanthomatosis. 61
21955034 2012
11
New mutations in APOB100 involved in familial hypobetalipoproteinemia. 61
21122650 2010
12
[A comparative study of the efficacy and safety Zhibitai and atorvastatin]. 61
20646412 2010
13
[Primary bilateral lipid keratopathy]. 61
19466688 2009
14
[Obesity and insulin resistance among adolescents from Chiapas]. 61
19593490 2009
15
Hypolipoproteinemia and hyperinflammatory cytokines in serum of severe and moderate traumatic brain injury (TBI) patients. 61
17993453 2007
16
[Drug-induced hypolipoproteinemia]. 61
17824104 2007
17
Thematic review series: patient-oriented research. What we have learned about VLDL and LDL metabolism from human kinetics studies. 61
16720894 2006
18
Tangier disease four decades of research: a reflection of the importance of HDL. 61
16611066 2006
19
[Hypolipoproteinemia and secondary role of atherosclerosis in the development of ischemic heart disease in patients with polycythemia vera]. 61
15699934 2005
20
Gene therapy for genetic lipid disorders: lipoprotein lipase deficiency as a paradigm. 54
15719845 2005
21
Characteristics of lipids imbalance in patients with tick-borne encephalitis. 61
15560094 2004
22
Expression pattern and raft association of NIPSNAP3 and NIPSNAP4, highly homologous proteins encoded by genes in close proximity to the ATP-binding cassette transporter A1. 54
15177564 2004
23
Familial HDL deficiency due to ABCA1 gene mutations with or without other genetic lipoprotein disorders. 54
15019541 2004
24
ATP-binding cassette (ABC) transporters in human metabolism and diseases. 54
15209530 2004
25
A novel two nucleotide deletion in the apolipoprotein A-I gene, apoA-I Shinbashi, associated with high density lipoprotein deficiency, corneal opacities, planar xanthomas, and premature coronary artery disease. 61
14709355 2004
26
Expression, regulation, and activity of ABCA1 in human cell lines. 54
12706378 2003
27
A prospective study of the association between APOE genotype and the risk of myocardial infarction among apparently healthy men. 54
12535745 2003
28
Differentiating hyperlipidaemia associated with antiretroviral therapy. 54
12545078 2003
29
[Familial hypolipoproteinemia with liver steatosis]. 61
12239658 2002
30
ABCA1 mRNA and protein distribution patterns predict multiple different roles and levels of regulation. 61
11896206 2002
31
Can measurement of apolipoprotein B replace the lipid profile in the follow-up of patients with lipoprotein disorders? 54
11861429 2002
32
Expression and functional analyses of novel mutations of ATP-binding cassette transporter-1 in Japanese patients with high-density lipoprotein deficiency. 54
11785958 2002
33
Homogeneous assay based on 52 primer sets to scan for mutations of the ABCA1 gene and its application in genetic analysis of a new patient with familial high-density lipoprotein deficiency syndrome. 54
11476961 2001
34
High-density single-nucleotide polymorphism (SNP) map of the 150-kb region corresponding to the human ATP-binding cassette transporter A1 (ABCA1) gene. 54
11558901 2001
35
Decreased expression of a member of the Rho GTPase family, Cdc42Hs, in cells from Tangier disease - the small G protein may play a role in cholesterol efflux. 61
11078892 2000
36
Familial hypercholesterolemia. Acceptor splice site (G-->C) mutation in intron 7 of the LDL-R gene: alternate RNA editing causes exon 8 skipping or a premature stop codon in exon 8. LDL-R(Honduras-1) [LDL-R1061(-1) G-->C]. 61
10487495 1999
37
A critical evaluation of the putative role of C3adesArg (ASP) in lipid metabolism and hyperapobetalipoproteinemia. 61
10698341 1999
38
Gene therapy for dyslipidemia: clinical prospects. 54
11122693 1999
39
Cholesterol paradox in patients with paroxysmal atrial fibrillation. 61
10640793 1999
40
Cellular cholesterol transport and efflux in fibroblasts are abnormal in subjects with familial HDL deficiency. 61
9888879 1999
41
Haplotypes of the ApoA-I/C-III/A-IV gene cluster and familial combined hyperlipidemia. 61
9812922 1998
42
[New approach from lipoprotein disorders to atherosclerosis]. 61
9721537 1998
43
Linkage of familial combined hyperlipidaemia to chromosome 1q21-q23. 61
9537421 1998
44
A competitive reverse transcription-PCR to study apolipoprotein epsilon gene expression. 61
9554488 1998
45
Lipoprotein disorder in brain infarction and hemorrhage. 61
9594362 1998
46
Etiologic heterogeneity of hyperapobetalipoproteinemia (hyperapoB). Results from segregation analysis in families with premature coronary artery disease. 61
9409249 1997
47
Elevated Lp(a) is the most frequent familial lipoprotein disorder leading to premature myocardial infarction in a country with low cholesterol levels. 61
9261642 1997
48
Interferon alpha induces disorder of lipid metabolism by lowering postheparin lipases and cholesteryl ester transfer protein activities in patients with chronic hepatitis C. 54
9185775 1997
49
Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis. 61
9199276 1997
50
Familial lipoprotein lipase (LPL) deficiency: a catalogue of LPL gene mutations identified in 20 patients from the UK, Sweden, and Italy. 54
9401010 1997

Variations for Hypolipoproteinemia

Expression for Hypolipoproteinemia

Search GEO for disease gene expression data for Hypolipoproteinemia.

Pathways for Hypolipoproteinemia

Pathways related to Hypolipoproteinemia according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.79 SCARB1 SAR1B PLTP PCSK9 MTTP LPL
2
Show member pathways
12.61 LPL APOE APOC3 APOC2 APOB APOA2
3
Show member pathways
12.24 SCARB1 APOE APOB APOA1 ABCA1
4
Show member pathways
12.2 LPL APOE APOC3 APOC2 APOB APOA2
5
Show member pathways
12.14 SCARB1 SAR1B PLTP PCSK9 MTTP LPL
6
Show member pathways
11.98 SCARB1 PLTP PCSK9 MTTP MIR33A LPL
7
Show member pathways
11.85 SCARB1 APOE APOB APOA1
8 11.69 PLTP LPL APOC3 APOA2 APOA1
9 11.66 SCARB1 SAR1B MIR33A LPL
10
Show member pathways
11.4 SCARB1 MTTP APOB APOA1 ABCG5 ABCA1
11 11.37 SCARB1 LPL ABCG5
12 11.32 MIR33A ABCG5 ABCG1 ABCA1
13 11.15 PLTP APOC3 APOA2 APOA1
14 11.08 SCARB1 APOB APOA1
15 10.95 APOA2 APOA1 ABCG1 ABCA1
16 10.84 MIR33A ABCA1

GO Terms for Hypolipoproteinemia

Cellular components related to Hypolipoproteinemia according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.27 PLTP PCSK9 LPL LPA LCAT CETP
2 extracellular space GO:0005615 10.21 PLTP PCSK9 LPL LCAT CETP APOE
3 extracellular exosome GO:0070062 10.15 SCARB1 LCAT CETP APOE APOC3 APOB
4 Golgi apparatus GO:0005794 10.08 SAR1B PCSK9 MTTP APOE ANGPTL3 ABCG1
5 cell surface GO:0009986 10 SCARB1 PCSK9 LPL APOA1 ANGPTL3 ABCA1
6 endoplasmic reticulum lumen GO:0005788 9.95 PCSK9 MTTP APOE APOB APOA2 APOA1
7 early endosome GO:0005769 9.92 PCSK9 APOE APOC3 APOC2 APOB APOA2
8 low-density lipoprotein particle GO:0034362 9.71 APOE APOC2 APOB APOA1
9 chylomicron GO:0042627 9.7 LPL APOE APOC3 APOC2 APOB APOA2
10 endocytic vesicle lumen GO:0071682 9.67 APOE APOB APOA1
11 spherical high-density lipoprotein particle GO:0034366 9.67 APOC3 APOC2 APOA2 APOA1
12 intermediate-density lipoprotein particle GO:0034363 9.65 APOE APOC3 APOC2 APOB APOA1
13 discoidal high-density lipoprotein particle GO:0034365 9.51 APOE APOA1
14 very-low-density lipoprotein particle GO:0034361 9.5 LPL APOE APOC3 APOC2 APOB APOA2
15 high-density lipoprotein particle GO:0034364 9.23 PLTP LCAT CETP APOE APOC2 APOB

Biological processes related to Hypolipoproteinemia according to GeneCards Suite gene sharing:

(show top 50) (show all 88)
# Name GO ID Score Top Affiliating Genes
1 steroid metabolic process GO:0008202 10.16 PCSK9 LCAT CETP APOE APOB APOA1
2 response to drug GO:0042493 10.13 LPL APOC2 APOA2 APOA1 ABCG5 ABCA1
3 retinoid metabolic process GO:0001523 10.13 LPL APOE APOC3 APOC2 APOB APOA2
4 intermembrane lipid transfer GO:0120009 10.13 PLTP MTTP CETP APOE APOB APOA2
5 post-translational protein modification GO:0043687 10.11 PCSK9 APOE APOB APOA2 APOA1
6 triglyceride homeostasis GO:0070328 10.11 SCARB1 MIR33A LPL CETP APOE APOC3
7 triglyceride metabolic process GO:0006641 10.1 PCSK9 MTTP LPL CETP APOE APOC3
8 lipoprotein metabolic process GO:0042157 10.1 PCSK9 MTTP APOE APOC3 APOB APOA2
9 reverse cholesterol transport GO:0043691 10.1 SCARB1 LCAT CETP APOE APOC3 APOC2
10 phospholipid transport GO:0015914 10.08 SCARB1 PLTP MTTP CETP APOA1 ABCA1
11 chylomicron assembly GO:0034378 10.08 MTTP APOE APOC3 APOC2 APOB APOA2
12 cholesterol transport GO:0030301 10.08 SCARB1 LCAT CETP APOB APOA2 APOA1
13 cellular protein metabolic process GO:0044267 10.07 PCSK9 APOE APOB APOA2 APOA1
14 chylomicron remodeling GO:0034371 10.07 LPL APOE APOC3 APOC2 APOB APOA2
15 high-density lipoprotein particle remodeling GO:0034375 10.07 SCARB1 PLTP LCAT CETP APOE APOC3
16 phospholipid efflux GO:0033700 10.05 APOE APOC3 APOC2 APOA2 APOA1 ABCG1
17 phospholipid metabolic process GO:0006644 10.04 PCSK9 LPL LCAT APOA1 ANGPTL3
18 low-density lipoprotein particle remodeling GO:0034374 10.04 LPA CETP APOE APOB APOA2 ABCG1
19 receptor-mediated endocytosis GO:0006898 10.03 SCARB1 APOE APOB APOA1
20 very-low-density lipoprotein particle remodeling GO:0034372 10.02 LPL LCAT CETP APOE APOC2 APOA1
21 cholesterol efflux GO:0033344 10.02 SCARB1 APOE APOC3 APOC2 APOB APOA2
22 positive regulation of cholesterol efflux GO:0010875 10.01 PLTP APOE APOA1 ABCG1 ABCA1
23 phospholipid homeostasis GO:0055091 10 CETP APOA1 ANGPTL3 ABCG1 ABCA1
24 lipid transport GO:0006869 10 SCARB1 PLTP MTTP LPA CETP APOE
25 lipid catabolic process GO:0016042 9.99 LPL APOC3 APOC2 APOB
26 high-density lipoprotein particle clearance GO:0034384 9.99 SCARB1 APOE APOC2 APOA2 APOA1
27 lipoprotein biosynthetic process GO:0042158 9.97 LCAT APOE APOB APOA1 ABCA1
28 cholesterol metabolic process GO:0008203 9.96 PCSK9 LCAT CETP APOE APOB APOA2
29 regulation of lipid metabolic process GO:0019216 9.93 APOA2 APOA1 ABCA1
30 positive regulation of catalytic activity GO:0043085 9.93 APOE APOC2 APOA2
31 high-density lipoprotein particle assembly GO:0034380 9.93 APOE APOA2 APOA1 ABCA1
32 chylomicron remnant clearance GO:0034382 9.93 APOE APOC3 APOC2 APOB
33 response to nutrient GO:0007584 9.92 APOA1 ABCG5 ABCA1
34 regulation of Cdc42 protein signal transduction GO:0032489 9.92 APOE APOC3 APOA1 ABCA1
35 lipid homeostasis GO:0055088 9.89 CETP APOE ANGPTL3
36 phosphatidylcholine biosynthetic process GO:0006656 9.87 LCAT APOA2 APOA1
37 triglyceride catabolic process GO:0019433 9.86 LPL APOC3 APOB
38 artery morphogenesis GO:0048844 9.85 APOE APOB ANGPTL3
39 low-density lipoprotein particle clearance GO:0034383 9.85 SCARB1 PCSK9 APOB
40 phosphatidylcholine metabolic process GO:0046470 9.85 LCAT CETP APOA1
41 lipoprotein transport GO:0042953 9.84 MTTP APOC2 APOB
42 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.84 CETP ABCG1 ABCA1
43 very-low-density lipoprotein particle assembly GO:0034379 9.83 MTTP APOC3 APOB
44 positive regulation of cholesterol esterification GO:0010873 9.83 APOE APOA2 APOA1
45 positive regulation of cholesterol storage GO:0010886 9.82 SCARB1 LPL APOB
46 negative regulation of very-low-density lipoprotein particle remodeling GO:0010903 9.81 APOC3 APOA2 APOA1
47 lipid metabolic process GO:0006629 9.8 PLTP PCSK9 MTTP LPL LPA LCAT
48 sterol transport GO:0015918 9.77 PLTP ABCG5
49 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.76 LPL APOB
50 endothelial cell proliferation GO:0001935 9.76 SCARB1 APOA1

Molecular functions related to Hypolipoproteinemia according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 10.05 LPL APOE APOA2 APOA1 ANGPTL3 ABCA1
2 lipid binding GO:0008289 10.03 PLTP MTTP CETP APOE APOC3 APOC2
3 heparin binding GO:0008201 9.95 LPL LPA APOE APOB ANGPTL3
4 protein heterodimerization activity GO:0046982 9.94 MTTP APOA2 ABCG5 ABCG1
5 phospholipid binding GO:0005543 9.93 APOE APOC3 APOB APOA2 APOA1 ABCG1
6 amyloid-beta binding GO:0001540 9.8 SCARB1 APOE APOA1
7 ATPase activity, coupled to transmembrane movement of substances GO:0042626 9.8 ABCG5 ABCG1 ABCA1
8 phosphatidylcholine binding GO:0031210 9.8 PLTP CETP APOA2 APOA1 ABCA1
9 low-density lipoprotein particle receptor binding GO:0050750 9.76 PCSK9 APOE APOB
10 low-density lipoprotein particle binding GO:0030169 9.74 SCARB1 PLTP PCSK9
11 phospholipid transporter activity GO:0005548 9.73 MTTP CETP ABCA1
12 cholesterol binding GO:0015485 9.73 CETP APOC3 APOA2 APOA1 ABCG1 ABCA1
13 high-density lipoprotein particle binding GO:0008035 9.72 SCARB1 PLTP APOA2 APOA1 ABCA1
14 lipoprotein particle binding GO:0071813 9.71 LPL APOE APOA1
15 phosphatidylcholine-sterol O-acyltransferase activator activity GO:0060228 9.7 APOE APOA2 APOA1
16 apolipoprotein A-I binding GO:0034186 9.69 SCARB1 LCAT ABCA1
17 high-density lipoprotein particle receptor binding GO:0070653 9.67 APOC3 APOA2 APOA1
18 lipase inhibitor activity GO:0055102 9.67 APOC3 APOC2 APOA2 APOA1
19 apolipoprotein receptor binding GO:0034190 9.65 PCSK9 APOA2 APOA1
20 heparan sulfate proteoglycan binding GO:0043395 9.63 LPL APOE
21 lipid transporter activity GO:0005319 9.63 MTTP APOE APOB APOA2 APOA1 ABCA1
22 phosphatidylcholine-translocating ATPase activity GO:0090554 9.62 ABCG1 ABCA1
23 very-low-density lipoprotein particle receptor binding GO:0070326 9.61 PCSK9 APOE
24 very-low-density lipoprotein particle binding GO:0034189 9.61 PLTP PCSK9
25 intermembrane phospholipid transfer activity GO:0120014 9.6 PLTP MTTP
26 triglyceride binding GO:0017129 9.59 LPL CETP
27 apolipoprotein binding GO:0034185 9.43 SCARB1 PCSK9 MTTP LPL LPA ABCA1
28 intermembrane cholesterol transfer activity GO:0120020 9.28 PLTP CETP APOE APOB APOA2 APOA1

Sources for Hypolipoproteinemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
67